Trial Profile
A Phase II clinical study of response to zoledronic acid therapy for bone metastases in patients with non-small cell lung carcinoma as assessed by positron emission tomography (PET).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LoPeZ
- 30 Aug 2011 New trial record